Open AccessSphingosine-1-phosphate inhibits the adipogenic differentiation of 3T3-L1 preadipocytes
Author(s) -
MyungHee Moon,
JaeKyo Jeong,
You-Jin Lee,
JaeWon Seol,
Sang-Youel Park
Publication year - 2014
Publication title -
international journal of molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.048
H-Index - 90
eISSN - 1791-244X
pISSN - 1107-3756
DOI - 10.3892/ijmm.2014.1856
Subject(s) - adipogenesis , sphingosine , sphingosine 1 phosphate , microbiology and biotechnology , sphingosine kinase , 3t3 l1 , mapk/erk pathway , biology , sphingosine kinase 1 , protein kinase a , transcription factor , adipose tissue , receptor , kinase , chemistry , endocrinology , biochemistry , gene
Sphingosine-1-phosphate (S1P) is a pluripotent lipid mediator that transmits signals through G-protein-coupled receptors to control diverse biological processes. The novel biological activity of S1P in the adipogenesis of 3T3-L1 preadipocytes was identified in the present study. S1P significantly decreased lipid accumulation in maturing preadipocytes in a dose‑dependent manner. In order to understand the anti‑adipogenic effects of S1P, preadipocytes were treated with S1P, and the change in the expression of several adipogenic transcription factors and enzymes was investigated using quantitative RT-PCR. S1P downregulated the transcriptional levels of the peroxisome proliferator-activated receptor γ, CCAAT/enhancer binding proteins and adiponectin, which are markers of adipogenic differentiation. The effects of S1P on the levels of mitogen‑activated protein kinase (MAPK) signals in preadipocytes were also investigated. The activation of JNK and p38 were downregulated by S1P treatment in human preadipocytes. In conclusion, the results of this study suggest that S1P alters fat mass by directly affecting adipogenesis. This is mediated by the downregulation of adipogenic transcription factors and by inactivation of the JNK and p38 MAPK pathways. Thus, selective targeting of the S1P receptors and sphingosine kinases may have clinical applications for the treatment of obesity.